A randomized trial from DRCR.net has shown ranibizumab is as effective as panretinal photocoagulation in treating PDR, and better than laser in preserving patients’ peripheral and night vision.
Powered by Finanznachrichten
AAO News Archive
- Deal struck to develop integrin antagonist treatment
- New low-add multifocal IOLs yield higher patient satisfaction
- Regeneron, Bayer to develop AMD combination therapy
- FDA approves wide-field imaging system for newborns
- Brain mapping may someday lead to vision-restoring therapies
- FDA warns of loose safety seals on eye drops
- Stem cells regrow human lens, corneal tissue
Ranibizumab comparable to laser for PDR
- Details